James V. Cassella - Jan 28, 2022 Form 4 Insider Report for CONCERT PHARMACEUTICALS, INC. (CNCE)

Role
Chief Development Officer
Signature
/s/ Jeffrey A. Munsie, attorney-in-fact
Stock symbol
CNCE
Transactions as of
Jan 28, 2022
Transactions value $
$0
Form type
4
Date filed
2/1/2022, 03:03 PM
Previous filing
Jan 7, 2022
Next filing
Feb 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNCE Common Stock Award +75.8K +91.23% 159K Jan 28, 2022 Direct F1, F2
transaction CNCE Common Stock Award +34.7K +21.84% 194K Jan 28, 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in equal annual installments over a three-year period measured from the date of grant. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.
F2 Not applicable.
F3 Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest one business day after the date on which the Food and Drug Administration notifies the Issuer that it has accepted for filing a New Drug Application for CTP-543, provided that the date of acceptance is on or before a certain date in 2023. The amount listed represents the maximum number of shares that may be delivered pursuant to the grant.